ALTEOGEN Inc.
KOE: 196170.KQ0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Soon-Jae Park
- Employees
- 145
- Headquarters
- Daejeon, South Korea
- IPO year
- 2014
- Market cap
- ₩18.2T
- Website
- https://www.alteogen.com
Loading 196170…
Loading profile data…Frequently asked questions about 196170
What does ALTEOGEN Inc. (196170.KQ) do?
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based...
Where does 196170.KQ trade?
ALTEOGEN Inc. (196170.KQ) trades on the KOSDAQ.
What sector is 196170.KQ in?
ALTEOGEN Inc. (196170.KQ) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of ALTEOGEN Inc.?
Soon-Jae Park is the chief executive officer of ALTEOGEN Inc. (196170.KQ).
Where is ALTEOGEN Inc. headquartered?
ALTEOGEN Inc. is headquartered in South Korea.
Does 196170.KQ pay a dividend?
Yes — ALTEOGEN Inc. (196170.KQ) paid a trailing twelve-month dividend of KRW 371.00 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 196170.KQ go public?
ALTEOGEN Inc. (196170.KQ) completed its initial public offering in 2014.